Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra
World Health Organization Wants Prices Lowered
Executive Summary
The World Health Organization has taken the unusual step of calling for lower drug prices to help COVID-19 patients access IL-6 therapies in developing nations.
You may also be interested in...
Hetero To Debut Biosimilar Actemra, Giving India Grasp On Supplies Security
The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.
Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’
The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.
More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.